We then used the GEPIA tool to assess the correlation between RASAL2-AS1 expression and patient survival, finding that higher RASAL2-AS1 levels were linked to poorer overall survival in HNSCC patients (Fig. 1C). This evidence concerns the gene RASAL2 and head and neck squamous cell carcinoma.